GlobeNewsWire
01 Jun 2026, 05:30 UTC · 23w ago
Verdict
Headline takes no side. We score UCB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Dapirolizumab pegol (DZP) met its primary endpoint in the Phase 3 PHOENYCS GO study, showing statistically significant improvement in SLE disease activity compared to placebo.
More positive than 93% of claims this week
DZP failed to meet its first key secondary endpoint (BICLA response at week 24).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 77% of claims this week
The drug demonstrated a glucocorticoid-sparing effect, allowing more patients to reduce their steroid dose compared to the placebo group.
More positive than 62% of claims this week
UCB and Biogen are progressing with the confirmatory Phase 3 PHOENYCS FLY study to support future regulatory filings.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Positive Phase 3 results for dapirolizumab pegol in SLE treatment were published in The Lancet.
More positive than 87% of ticker scores this week
Positive Phase 3 results for dapirolizumab pegol in SLE treatment were published in The Lancet.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
8m ago
+14.1%
Price agrees with the score
$37.60 vs $32.95 close before publication (May 29) · not market-adjusted
UCB chart →
